Geneva Network

Civil society statement on EU innovation incentives review

Read our statement calling upon the European Commission to put innovation at the centre of its review into pharmaceutical innovation incentives.

Colombia OECD

17th April 2018/by gnadm

Is the OECD ready for Colombian membership?

15th February 2018/by gnadm

Delinked from reality

8th November 2017/by gnadm

Vaccines: accelerating innovation and access

11th July 2017/by Eve Parker

Why regulatory data protection matters for medicines

30th June 2017/by gnadm

Enantiomer patents – a necessary incentive

22nd May 2018/by gnadm

The World Health Organization’s lack of focus risks global health

18th December 2017/by gnadm

Letter to the European Commission on the review of pharmaceutical innovation incentives

8th December 2017/by gnadm

NAFTA and health: how trade improves health

Delinkage requires big tax increases

28th November 2017/by gnadm

Delinkage: can prizes replace patents for medicine innovation?

Supplementary Protection Certificates

16th November 2017/by gnadm

The European Commission’s muddle on pharmaceutical innovation incentives